The outcomes regarding steatosis, inflammation, and hepatic ballooning were assessed histologically using the NAFLD activity score, which significantly decreased upon RNase 1 treatment (Figure 5H). This evidence concerns the gene RNASE1 and metabolic dysfunction-associated steatotic liver disease.